(Q47426455)

16 January 2018

title

The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? (English)

1 reference

16 January 2018

The low α/β ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us? (English)

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00747-8

24 March 2024

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00747-8

24 March 2024

author name string

Jian Z. Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575842

24 March 2024

X. Allen Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575842

24 March 2024

Cedric X. Yu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575842

24 March 2024

Steven J. DiBiase

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14575842

24 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

16 January 2018

15 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14575842

full work available at URL

24 March 2024

https://api.elsevier.com/content/article/PII:S0360301603007478?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00747-8

https://api.elsevier.com/content/article/PII:S0360301603007478?httpAccept=text/plain

24 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0360-3016(03)00747-8

International Journal of Radiation Oncology Biology Physics

24 March 2024

published in

1 reference

16 January 2018

volume

57

1 reference

16 January 2018

issue

4

1 reference

16 January 2018

page(s)

1101-1108

1 reference

16 January 2018

Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

How low is the alpha/beta ratio for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Is the prostrate alpha/beta ratio of 1.5 from Brenner & Hall a modeling artifact

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Toward optimal external-beam fractionation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Hypofractionation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Is alpha/beta for prostate tumors really low?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Is the alpha/beta ratio for prostate cancer low?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

The prospects for new treatments for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Is the alpha/beta for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-1031.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

In regard to Brenner et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio) similar to late-responding normal tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Prostate cancer: low alpha/beta the only consideration? In regard to Fowler, Chappell, and Ritter: the prospects for new treatments for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Yes, the alpha/beta ratio for prostate cancer is low or "methinks the lady doth protest too much...about a low alpha/beta that is"

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

An 'incomplete-repair' model for survival after fractionated and continuous irradiations.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

A comment on proliferation rates in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT).

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900747-8

7 January 2021

Identifiers

1 reference

16 January 2018

1 reference

16 January 2018